Age-related macular degeneration (AMD) is a major cause of visual impairment in elderly people in the Western world.^[@R1],[@R2]^ Risk factors include smoking, eating habits, genetic background, and recently an association with the gut microbiome has been demonstrated.^[@R3]--[@R5]^ The development of choroidal neovascularization secondary to AMD is an attribute of exudative AMD. The pivotal trials for exudative AMD have shown that monthly or bimonthly injections lead to an excellent functional and anatomical outcome. However, subsequent trials have found that these results were not maintained after switching to a pro re nata (PRN) regimen, and long-term studies have shown that the initial gain in visual acuity is largely obliterated after 5 years of treatment.^[@R6],[@R7]^

We have recently analyzed outcomes of our patients when terminating a PRN regimen.^[@R8]^ We found that only 2.6% of patients were able to terminate treatment after reaching predefined exit criteria. These criteria required 3 monthly injections for 1 year, followed by 2 injections 6 months apart in the second year with stable disease, defined as no intraretinal fluid (IRF) or subretinal fluid (SRF).

To reduce treatment burden and the need for monthly follow-ups, the treat-and-extend regimen has become popular in recent years. In this treatment regimen, administration of injections is guided by optical coherence tomography (OCT) findings with either extension or decrease of treatment intervals, depending on disease activity.^[@R9]^ Although the extension and decrease of intervals seems to be quite uniform in published reports,^[@R10]--[@R12]^ there is still considerable debate about which maximum interval is reasonable and there is little, if none, data on outcomes of exit strategies when treating patients with a treat-and-extend approach. In the treat-and-extend regimen used at our institution, the maximal interval is 16 weeks, and "exit criteria" are defined as 3 consecutive injections with an interval of 16 weeks with stable findings. "Exit" describes the termination of anti--vascular endothelial growth factor (VEGF) treatment after reaching the exit criteria.

The aim of this retrospective study was to evaluate the outcome of a predefined exit strategy using a treat-and-extend regimen for exudative AMD.

Methods {#s1}
=======

Patient Selection {#s1-1}
-----------------

Patients with neovascular AMD receiving intravitreal injections under a treat-and-extend regimen with ranibizumab or aflibercept for exudative AMD were identified in our institutional database at the Department of Ophthalmology at the University Hospital Bern, Switzerland. Ethics approval (KEK-Nr. 093/13) to conduct this study was obtained from the local ethics committee, which is working in accordance with ICH-GCP guidelines. The study was conducted in compliance with the tenets of the Declaration of Helsinki.

None of the patients had previous photodynamic therapy. Subjects who had discrepancies of more than 2 weeks between the scheduled visit and the effective visit were excluded from the evaluation of the treatment intervals. Patients who reached the exit criteria until August 31, 2016, were identified, and the number of injections, duration of therapy, and intervals between the injections were analyzed.

Treat-and-Extend Regimen {#s1-2}
------------------------

An outline illustrating the Bern treat-and-extend regimen is shown in Figure [1](#F1){ref-type="fig"}. Briefly, in this regimen, patients receive an injection at each visit in addition to early treatment diabetic retinopathy study (ETDRS) visual acuity testing and spectral domain OCT imaging (Heidelberg Engineering, Heidelberg, Germany). All patients receive a second anti-VEGF injection 4 weeks after the first injection. Depending on the findings in OCT and on ETDRS visual acuity, the intervals are then adjusted as follows: The treatment interval is extended by 2 weeks if stable disease is present. Stable disease is defined as no evidence of intra--retinal pigment epithelium (RPE), subretinal RPE, or sub-RPE fluid in the OCT; SRF below the fovea \<50 *μ*m (measured with digital calipers) and no change in subretinal RPE and sub-RPE fluid and stable visual acuity at the third consecutive examination (within five ETDRS letters of either of the last three visits). A localized pigment epithelial detachment (PED) was not attributed to disease activity and would allow for further extension of treatment intervals. The interval to the next injection is to be shortened by 1 week if there are signs of activity. When the interval had to be shortened and stable disease is seen in 2 following examinations, this interval must not be extended for the next 6 months. After 6 months, the intervals can be extended again after the treat-and-extend regimen.

![Outline of the Bern treat-and-extend regimen for AMD: Four weeks after the first intravitreal injection (IVT) with an anti-VEGF, a second injection is given. Depending on the OCT findings, the interval to the following injection is adjusted. The treatment interval is extended by 2 weeks if stable disease is present or shortened, respectively, by 1 week if there are signs of activity, defined as IRF and/or SRF. When the interval had to be shortened, this interval must not be extended for the next 6 months but may be shortened in case of activity at any visit. After 6 months, the intervals can be extended again. The exit criteria are reached if the maximal interval of 16 weeks is reached and maintained for 3 consecutive injections.](retina-39-27-g001){#F1}

The exit criteria are defined as follows: when the interval is extended to 16 weeks and the findings are stable, the interval of 16 weeks is maintained for 3 consecutive injections before therapy is stopped. Subsequently, only follow-up visits are planned every 3 to 4 months.

According to this regimen, the minimal number of injections from the start of therapy to the exit is 10, with a minimum duration of therapy of about 2 years (Figure [2](#F2){ref-type="fig"}).

![Outline of the minimal number of injections (10) according to the treat-and-extend regimen from the start of therapy to the exit with a minimum duration of therapy of about 2 years.](retina-39-27-g002){#F2}

Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) at initiation and termination of treatment, the number of injections and intervals between the injections, duration of therapy as well as the incidence of recurrence after termination of treatment were investigated.

Evaluation of Optical Coherence Tomography Characteristics {#s1-3}
----------------------------------------------------------

The presence or absence of characteristics in the OCT images was identified for all patients who fulfilled the exit criteria including: atrophy, subretinal hyperreflective material, IRF or SRF, and PED. These characteristics were defined as the following: IRF was identified as hyporeflective spaces within the neurosensory retina of \>25 *μ*m, whereas SRF was defined as a nonreflective space between the RPE and the posterior boundary of the neurosensory retina. A PED was identified as an elevation of the RPE band and included serous (evidenced by hyporeflective internal reflectivity) as well as fibrovascular PED (evidenced by heterogeneous internal reflectivity). Atrophy was defined as a sharply delineated area with loss of the RPE band and consequent hyperreflectivity of the choriocapillaris. Continuous hyperreflective subretinal tissue between neurosensory retina and Bruch membrane was described as "subretinal hyperreflective material". Optical coherence tomography images were analyzed at initiation and termination of treatment.

Statistical Analysis {#s1-4}
--------------------

Data analysis was performed using GraphPad Prism version 5.02 for Windows (GraphPad Software, La Jolla, CA), [www.graphpad.com](http://www.graphpad.com).

Significance testing for the differences in OCT characteristics of the subgroups was performed using Fisher\'s exact test. To compare the changes in BCVA and CRT within all included eyes, a paired *t*-test was used, and to compare differences in the mean changes of BCVA and CRT in the subgroups, an unpaired *t*-test was used. A *P* value less than 0.05 was stated as significant.

Results {#s2}
=======

A total of 655 eyes of 533 patients treated with ranibizumab or aflibercept within the period between January 1, 2014, and December 31, 2015, were identified. Fifty eyes had to be excluded with less than 3 injections and 7 eyes that were switched either to aflibercept or ranibizumab. The inclusion criteria were met by 598 eyes of 488 patients.

The mean age was 80 ± 9 years (range 50--95 years), about two-thirds of the patients were female (63%). Seventeen percent (100 eyes) of all included eyes of 95 patients met the exit criteria. The demographic data of patients who met the exit criteria were comparable with the entire patient cohort in this study, with a mean age of 80 ± 9 years (range 51--92 years) and 64% female patients. In the patient cohort, meeting the exit criteria, the mean number of anti-VEGF injections was 23.7 ± 14.7 with a mean treatment duration of 236 ± 130 weeks (4.5 ± 2.5 years). Fluorescein angiography before treatment revealed 59 cases (59%) of occult choroidal neovascularization, 30 cases (30%) of predominantly classic choroidal neovascularization, and 2 cases (2%) of polypoidal choroidal vasculopathy. In nine cases (9%), no fluorescein angiography was performed before treatment, and diagnosis was based on OCT.

There was no significant change in BCVA from the start to termination of therapy (62.2 ± 13.3 vs. 62.2 ± 17.5, *P* = 0.80), whereas CRT decreased significantly until the exit criteria were reached (366 ± 104 *μ*m vs. 271 ± 55 *μ*m, *P* \< 0.0001).

Twelve eyes (of 12 patients) received a minimal number of 10 injections (12% of all eyes that met the exit criteria). This group of patients is called "rapid responders" in the following. The OCT characteristics for the groups of rapid and nonrapid responders including presence of PED, IRF and SRF, subretinal hyperreflective material, and atrophy are listed in Table [1](#T1){ref-type="table"}A at start and in Table [1](#T1){ref-type="table"}B at termination of therapy. In the group of nonrapid responders, 30% of the OCT images at the start of therapy could not be evaluated because of the use of another OCT device before 2009 (images were not available). In the group of rapid responders, all initial OCTs were available.

###### 

Subgroup Analysis for Rapid and Nonrapid Responders

![](retina-39-27-g003)

Thirteen eyes (of 12 patients), which reached exit criteria, had recurrent disease after treatment termination. The mean duration of follow-up for all 100 eyes that met the exit criteria was 40.5 ± 26.6 weeks. Patients presenting with recurrent disease after a mean of 37 ± 16 weeks had a mean loss of −3.7 ± 15.9 ETDRS letters, with 2 patients presenting with a loss of more than 15 letters. None of the rapid responders showed recurrent disease activity within the observation period. The OCT characteristics for the subgroups with and without recurrence are listed in Table [2](#T2){ref-type="table"}A at start and in Table [2](#T2){ref-type="table"}B at termination of therapy, respectively. The only significant difference between the two groups was the presence of PED at the time point of treatment termination (77% vs. 30%, *P* = 0.0018) with a significant higher proportion of serous PED (31% vs. 7%, *P* = 0.0247).

###### 

Subgroup Analysis for Patients With Respectively Without Recurrent Disease

![](retina-39-27-g004)

Changes of the mean of BCVA and CRT between the subgroups rapid versus nonrapid responders and recurrent disease versus nonrecurrent disease were not significant: 6.1 ± 6.9 versus −0.4 ± 15.0 letters (*P* = 0.15) and −105.0 ± 103.6 versus −99.5 ± 117.3 *μ*m (*P* = 0.88), respectively, −4.9 ± 19.7 versus 1.2 ± 13.2 letters (*P* = 0.16) and −40.8 ± 148.0 versus −107.7 ± 108.2 *μ*m (*P* = 0.12).

Discussion {#s3}
==========

In this study, we analyzed the outcomes of an exit strategy in a treat-and-extend regimen for exudative AMD. An unexpectedly high proportion of eyes (17%) met these exit criteria. This is a considerably larger portion in comparison with our findings in 2014 where only 2.6% of patients terminated treatment according to predefined exit criteria using a capped PRN treatment approach.^[@R8]^ To understand this discrepancy, the respective peculiarities of the PRN and the treat-and-extend regimen need to be discussed. The PRN regimen mandates monthly follow-ups with anti-VEGF therapy, given only if there is disease activity. By contrast, treatment intervals in the treat-and-extend regimen are adjusted according to the last follow-up and anti-VEGF treatment is mandatory at each visit. Several studies have shown, although there are less injections in the PRN regimen, that there are significantly more follow-up consultations than in the treat-and-extend regimen.^[@R13]--[@R15]^ These differences between the two regimens provide possible explanations for the observed discrepancies. Because the PRN regimen requires monthly and therefore significantly more follow-up consultations with BCVA and OCT examinations than the treat-and-extend regimen,^[@R16]^ especially during stable disease, patients or the treating physicians may be more inclined to stop treatment without reaching the predefined exit criteria. Aside from one study, which evaluated factors influencing patients\' adherence in a PRN treatment regimen,^[@R17]^ little is known about treatment compliance with anti-VEGF treatment and how compliance compares between different treatment regimens. However, in addition to patients\' compliance, there are many other reasons why anti-VEGF is stopped. These include irreversible anatomical changes such as fibrovascular scar formation or RPE atrophy conflicting with further anti-VEGF treatment.

Another possible explanation is that patients may be undertreated in the PRN group with more disease recurrences. This, in turn, may have resulted in lower likelihood of reaching the predefined exit criteria in a PRN regimen. We have observed significantly less IRF or SRF after switching from a PRN regimen to a treat-and-extend regimen in a retrospective study.^[@R15]^ Two meta-analyses investigating the "real-world" outcome of treat-and-extend versus PRN regimens in neovascular AMD further confirm the assumption that treat and extend may be superior compared with PRN treatment with higher numbers of administered injections, less disease activity, and better maintenance of visual function.^[@R13],[@R18]^

Yet, another feature of the exit strategy merits further discussion. We are not aware of any consensus on the maximal treatment interval in a treat-and-extend regimen. Most studies have a maximal treatment interval of 12 weeks.^[@R10]--[@R12]^ Ideally, the maximal treatment interval should allow to observe the patient under conditions when anti-VEGF levels have fallen below therapeutic levels. In a prospective clinical study, the mean suppression time after ranibizumab injections was determined to be approximately 36.4 days but showed a wide range between 26 and 69 days.^[@R19]^ Aflibercept was shown to have a longer suppression time after injection of 70.5 ± 18.0 days with a range between 41 and 109 days.^[@R20]^ As such, at least for ranibizumab, the minimal duration for the maximal interval would be set at 10 weeks, for aflibercept possibly up to 15 to 16 weeks. However, there is likely to be a delay between reaching subtherapeutic levels in the vitreous and disease recurrence and as such, a longer maximal interval is likely to result in better safety for patients.^[@R21]^ However, it remains unclear which maximal treatment interval warrants for a stable level of VEGF suppression. It should be pointed out that in clinical practice, only the anatomical response is measured but not the VEGF levels. In comparison with published treatment regimens,^[@R10],[@R12],[@R22],[@R23]^ we have used a longer maximal extension interval of 16 weeks. To evaluate sustained disease stability, this maximal interval of 16 weeks had to be maintained over the course of 1 year, before treatment could be terminated.

A large retrospective study showed that the risk of reactivation reached 37.4% at treatment intervals of ≥20 weeks. This would suggest that there is a considerable proportion of patients who would benefit from continued treatment at the maximum interval. However, these data contrast with our considerably lower recurrence rate of 13% after termination of treatment and a mean interval to recurrence since the last injection of approximately 9 months. One possible explanation could be the quite variable maximal treatment interval in the former study where intervals from 126 to 365 days were classified as 20 weeks.^[@R24]^ Eyes with recurrence in our study only had an average loss of −3.7 ± 15.9 ETDRS letters, with only 2 eyes presenting with a loss of more than 15 letters. This suggests that only a very small percentage (2%) of eyes have a recurrence significantly affecting visual function when stopping treatment according to our exit criteria.

The same study reported that in the 86.5% of eyes treated with a treat-and-extend regimen and that never showed a reactivation, the injection interval could be extended to 12 weeks or more. But the risk of a disease recurrence was reported to increase with treatment intervals longer than 12 weeks, although the most common (17.4%) interval until reactivation reported was 8 weeks.^[@R24]^

In the analysis of the subgroups with respectively without recurrent disease, a significant higher rate of PED could be seen in the group with recurrences (77% vs. 30%, *P* = 0.0018) at termination of treatment. In the literature, PED was recently also described as the primary indicator reflecting progressive disease activity.^[@R25]^ Waldstein et al^[@R26]^ reported the highest rate of PED resolution in a monthly dosing regimen with aflibercept (39.5%) in comparison with a bimonthly dosing regimen with aflibercept and a monthly treatment with ranibizumab. These results imply that patients with PED need intensive anti-VEGF treatment and may require more long-term treatment than patients without persisting PED.

The mean BCVA change of all included eyes showed a wide range: changes between −47 and +33 letters were observed. This reflects the inhomogeneity within this group, especially about duration of treatment and also number of injections. However, the subgroup of rapid responders with a treatment duration of about 2 years showed a mean gain in BCVA of 6.1 ± 6.9 letters (range: −3 to +19 letters). Similar ranges of BCVA gains were reported in other treat-and-extend studies: mean BCVA gain after 1 year of 11.6,^[@R27]^ 10.8,^[@R16]^ 10.5,^[@R10]^ 7,^[@R23]^ 1.0 letters,^[@R24]^ respectively, a mean BCVA change after 2 years of +10.7^27^ and −0.6 letters.^[@R24]^ Furthermore, it is comparable with the data of Menke et al^[@R8]^ with a mean BCVA gain of 4.5 ± 16.9 letters in the group of patients who reached the exit criteria in a capped PRN treatment regimen based on the PIER study. Corresponding to a longer duration of treatment such as in the nonrapid responder group, a more pronounced BCVA loss would be expected. This is confirmed by the data of the SEVEN-UP study which reported a mean BCVA loss of −8.6 letters 7 years after treatment initiation.^[@R6]^ Moreover, the CATT study data showed that after 5 years of anti-VEGF treatment, the initial vision gain could not be maintained.^[@R7]^ The fact that initial gain of vision during the first year of treatment is lost in most long-term studies is in keeping with our data.

Limitations of this study include the small sample size and the retrospective design, which allows reporting of associations only. Time shifting of the planned visits occurred because of patients\' liabilities or illness. This may have led to a possible inconsistency of treatment intervals. In addition, there is a small percentage of patients without initial OCT images.

Our data underline the fact that anti-VEGF treatment for neovascular AMD is useful and effective in preserving vision in many, but not all patients. There is still no cure for neovascular AMD and anti-VEGF treatment, confronts the physician with numerous unsolved problems such as unknown long-term side effects (i.e., geographic atrophy), and lacking of alternative treatment options or exit strategies.

Predefined exit strategies will free up injection clinics and direct treatment efforts to patients who require intensive treatment. It further gives patients a potential outlook that no lifelong treatment may be needed. In our opinion, visits every 3 months after termination of anti-VEGF therapy, combined with thorough patient counseling, are sufficient to screen for recurrences, although further studies are warranted to prove and investigate the optimal visit interval. The high percentage of patients who met exit criteria and the relatively low incidence of recurrences underlines the usefulness of an exit strategy in treat-and-extend regimens. Although the risk of a recurrence seems small, regular follow-ups are important to diagnose and treat recurrences as early as possible. Adjusting of the stability criteria should be considered in the future, especially in the matter of PED as a risk factor for disease recurrence. Patients with persistent PED may benefit from protracted treatment at the maximal interval in a treat-and-extend regimen.
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